Basic Trial Information
Trial Description
     Summary
     Further Trial Information
     Eligibility Criteria
Trial Contact Information

Basic Trial Information

Trial Description

Summary

This randomized phase III trial is studying gemcitabine hydrochloride and erlotinib hydrochloride to see how well they work compared with gemcitabine hydrochloride alone followed by the same chemotherapy regimen with or without radiation therapy and capecitabine or fluorouracil in treating patients with pancreatic cancer that was removed by surgery. Drugs used in chemotherapy, such as gemcitabine hydrochloride, capecitabine, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high energy x-rays to kill tumor cells. Giving chemotherapy together with or without erlotinib hydrochloride and/or radiation therapy after surgery may kill any tumor cells that remain after surgery. It is not yet known whether chemotherapy is more effective when given with or without erlotinib hydrochloride and/or radiation therapy in treating pancreatic cancer

Further Study Information

PRIMARY OBJECTIVES:

I. To determine whether the addition of erlotinib hydrochloride to adjuvant chemotherapy comprising gemcitabine hydrochloride improves survival as compared to gemcitabine hydrochloride alone following R0 or R1 resection in patients with pancreatic adenocarcinoma.

II. To determine whether the use of concurrent fluoropyrimidine and radiotherapy following adjuvant gemcitabine hydrochloride-based chemotherapy further enhances survival of patients who have no evidence of progressive disease after 5 courses of gemcitabine hydrochloride-based chemotherapy.

SECONDARY OBJECTIVES:

I. To evaluate the disease-free survival of patients who are disease-free after 5 courses of adjuvant gemcitabine hydrochloride-based chemotherapy followed by fluoropyrimidine-based chemoradiotherapy.

II. To evaluate the disease-free survival of patients treated with adjuvant gemcitabine hydrochloride-based chemotherapy with vs without erlotinib hydrochloride.

III. To evaluate the disease-free and overall survival of patients stratified by wild-type and K-Ras status treated with adjuvant gemcitabine hydrochloride-based chemotherapy with vs without erlotinib hydrochloride.

IV. To evaluate adverse events associated with adjuvant gemcitabine hydrochloride-based chemotherapy with vs without erlotinib hydrochloride in these patients.

V. To evaluate adverse events associated with adjuvant gemcitabine hydrochloride-based chemotherapy with vs without fluoropyrimidine-based chemoradiotherapy in patients who are disease-free after adjuvant gemcitabine hydrochloride-based chemotherapy.

VI. To evaluate preoperative cross-sectional imaging of primary adenocarcinoma of the head of the pancreas in order to determine the frequency with which objective criteria of resectability are present.

VII. To determine the predictive roles of K-Ras mutations and epithelial to mesenchymal transition phenotype in response to epidermal growth factor receptor (EGFR) tyrosine kinase inhibition in early-stage pancreatic cancer.

VIII. To determine the frequency of EGFR-activated pathway and its influence on outcome.

IX. To determine the association between developmental molecular markers and outcome.

X. To determine the phenotype and genotype of tumors in patients with recurrence after resection.

XI. To determine if low baseline fatigue, as measured by the FACIT-Fatigue, predicts survival.

XII. To explore correlations between baseline fatigue, as measured by PROMIS, and survival.

OUTLINE: This is a multicenter study. Patients are stratified according to nodal status (involved vs uninvolved), CA19-9 result (≤ 90 IU/L vs 91-180 IU/L), and surgical margins (positive [R1] vs negative [R0]). Patients are randomized to 1 of 2 treatment arms.

ARM I: Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days for 5 courses in the absence of disease progression or unacceptable toxicity.

ARM II: Patients receive gemcitabine hydrochloride as in arm I and oral erlotinib hydrochloride once daily on days 1-28. Treatment repeats every 28 days for 5 courses in the absence of disease progression or unacceptable toxicity. Patients with no disease progression after treatment in arm I or II are then stratified according to their first randomization treatment arm (arm I vs arm II) and randomized to 1 of 2 additional treatment arms (arm III or IV).

ARM III: Patients receive 1 course of the same treatment that they receive in arm I or II.

ARM IV: Patients receive 1 course of the same treatment that they receive in arm I or II. Beginning within 7-21 days after completion of chemotherapy, patients undergo radiotherapy (3-dimensional conformal radiotherapy or intensity-modulated radiotherapy) 5 days per week for 5.5 weeks (28 fractions). During radiotherapy, patients receive either oral capecitabine twice daily 5 days per week or fluorouracil IV continuously for 5.5 weeks or until radiotherapy is completed.

After completion of study, patients are followed up periodically.

Eligibility Criteria

Inclusion Criteria:

• Histologically confirmed primary adenocarcinoma of the pancreatic head, neck, or uncinate process

• Intraductal papillary mucinous neoplasm or invasive adenocarcinoma allowed

• No non-adenocarcinoma, adenosquamous carcinoma, islet cell (neuroendocrine) tumor, cystadenoma, cystadenocarcinoma, carcinoid tumor, duodenal carcinoma, distal bile duct tumor, or ampullary carcinoma

• Pathologic stage T1-3, N0-1, M0 disease according to American Joint Committee on Cancer (AJCC) 6th edition

• Has undergone a potentially curative resection (i.e., removal of all gross tumor) involving a classic (Whipple) or a pylorus preserving pancreaticoduodenectomy within the past 21-56 days

• Operative report must contain a statement from the surgeon explicitly detailing that a total gross excision of the primary tumor was achieved

• Pathology report must include documentation of margin status, size of the tumor, and status of the 3 major surgical margins (bile duct, pancreatic parenchyma, and retroperitoneal [uncinate])

• Post-resection serum CA19-9 =< 180 IU/L

• Tumor tissue block and peripheral blood samples must be submitted to the study's central tumor bank for correlative studies

• No recurrent pancreatic cancer

• Zubrod performance status 0-1

• ANC >= 1,500/mm^3

• Platelet count >= 100,000/mm^3

• Hemoglobin >= 8.0 g/dL (transfusion or other intervention allowed)

• Serum total bilirubin =< 2 times upper limit of normal (ULN)

• Creatinine =< 2 times ULN

• SGOT =< 2.5 times ULN

• Not pregnant or nursing

• Negative pregnancy test

• Fertile patients must use effective contraception

• Suitable to receive study radiotherapy, as documented by a radiation oncologist

• Active HIV infection allowed provided the CD4 count is >= 499/mm^3 and the viral load is =< 50 copies/mL

• Total oral caloric intake >= 1,500 calories/day

• No significant nausea and vomiting

• None of the following severe active comorbidities that would preclude study therapy:

• Unstable angina and/or congestive heart failure requiring hospitalization within the past 6 months

• Transmural myocardial infarction within the past 3 months

• Acute bacterial or fungal infection requiring IV antibiotics

• Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy

• No other invasive malignancies within the past 2 years except for nonmelanomatous skin cancer or carcinoma in situ

• See Disease Characteristics

• No prior systemic chemotherapy for pancreatic cancer

• Prior chemotherapy for a different cancer allowed

• No prior total pancreatectomy, distal pancreatectomy, or central pancreatectomy

• No prior radiotherapy to the region of the study cancer that would result in overlap of radiotherapy fields

• Concurrent highly active antiretroviral treatment (HAART) allowed

Trial Contact Information

Trial Lead Organizations/Sponsors

National Cancer Institute

Ross Abrams

Principal Investigator

U.S.A.
California
	Auburn
	Auburn Radiation Oncology
		Christopher Jones	Ph: 916-646-8300
	Burbank
	Roy and Patricia Disney Family Cancer Center at Providence Saint Joseph Medical Center
		Raul R. Mena	Ph: 818-847-3220
	Cameron Park
	Radiation Oncology Centers - Cameron Park
		Christopher Jones	Ph: 916-646-8300
	Carmichael
	Mercy Cancer Center at Mercy San Juan Medical Center
		Christopher Jones	Ph: 916-646-8300
	Fresno
	California Cancer Center - Woodward Park Office
		Brent L. Kane	Ph: 559-447-4050
	Saint Agnes Cancer Center at Saint Agnes Medical Center
		Sri G Gorty	Ph: 909-865-9555
	Los Angeles
	USC/Norris Comprehensive Cancer Center and Hospital
		Syma Iqbal	Ph: 323-865-0451
		Syma Iqbal	Ph: 323-865-0451
	Oakland
	Alta Bates Summit Medical Center - Summit Campus
		James H. Feusner	Ph: 510-450-7600
	CCOP - Bay Area Tumor Institute
		James H. Feusner	Ph: 510-450-7600
	Kaiser Permanente-Oakland
		Louis Fehrenbacher	Ph: 626-564-3455
	Orange
	Chao Family Comprehensive Cancer Center at University of California Irvine Medical Center
		Tara E Seery	Ph: 877-827-8839
			Email: ucstudy@uci.edu
	Rancho Cardova
	Kaiser Permanente Medical Center - Rancho Cordova
		Louis Fehrenbacher	Ph: 626-564-3455
	Rohnert Park
	Rohnert Park Cancer Center
		Louis Fehrenbacher	Ph: 626-564-3455
	Roseville
	Radiation Oncology Center - Roseville
		Christopher Jones	Ph: 916-646-8300
	The Permanente Medical Group-Roseville Radiation Oncology
		Louis Fehrenbacher	Ph: 626-564-3455
	Sacramento
	Mercy General Hospital
		Christopher Jones	Ph: 916-646-8300
	Radiological Associates of Sacramento Medical Group, Incorporated
		Christopher Jones	Ph: 916-646-8300
	South Sacramento Cancer Center
		Louis Fehrenbacher	Ph: 626-564-3455
	San Diego
	Sharp Memorial Hospital Cancer Center
		Robert M. Barone	Ph: 858-939-5015
	San Francisco
	California Pacific Medical Center - California Campus
		Ari D Baron	Ph: 650-696-4487
			Email: PazE@sutterhealth.org
	Santa Clara
	Kaiser Permanente Medical Center - Santa Clara Homestead Campus
		Louis Fehrenbacher	Ph: 626-564-3455
	South San Francisco
	Kaiser Permanente Cancer Treatment Center
		Louis Fehrenbacher	Ph: 626-564-3455
	Vacaville
	Solano Radiation Oncology Center
		Christopher Jones	Ph: 916-646-8300
	Vallejo
	Sutter Solano Medical Center
		Ari D Baron	Ph: 650-696-4487
			Email: PazE@sutterhealth.org
Colorado
	Aurora
	Rocky Mountain Cancer Centers - Aurora
		Eduardo R. Pajon	Ph: 888-785-6789
	Boulder
	Boulder Community Hospital
		Eduardo R. Pajon	Ph: 888-785-6789
	Englewood
	Swedish Medical Center
		Eduardo R. Pajon	Ph: 888-785-6789
	Greeley
	North Colorado Medical Center
		Eduardo R. Pajon	Ph: 888-785-6789
	Littleton
	Rocky Mountain Cancer Centers - Littleton
		Eduardo R. Pajon	Ph: 888-785-6789
	Loveland
	McKee Medical Center
		Eduardo R. Pajon	Ph: 888-785-6789
	Thornton
	Rocky Mountain Cancer Centers - Thornton
		Eduardo R. Pajon	Ph: 888-785-6789
	Wheat Ridge
	Exempla Lutheran Medical Center
		Eduardo R. Pajon	Ph: 888-785-6789
Connecticut
	Bridgeport
	St. Vincent's Medical Center
		Stuart G Marcus	Ph: 203-576-6329
			Email: twhite@stvincents.org
	Hartford
	Helen and Harry Gray Cancer Center at Hartford Hospital
		Robert D. Siegel	Ph: 860-545-5363
	New Britain
	George Bray Cancer Center at the Hospital of Central Connecticut - New Britain Campus
		Neal B Goldberg	Ph: 860-224-5660
Delaware
	Newark
	Helen F. Graham Cancer Center at Christiana Hospital
		Adam Raben	Ph: 302-733-6227
Florida
	Fort Lauderdale
	Michael and Dianne Bienes Comprehensive Cancer Center at Holy Cross Hospital
		Michael Schwartz	Ph: 305-674-2625
			Email: info@msccop.com
	Jacksonville
	Mayo Clinic - Jacksonville
		Michael G. Haddock	Ph: 507-538-7623
	Miami
	University of Miami Sylvester Comprehensive Cancer Center - Miami
		Lorraine Portelance	Ph: 866-574-5124
			Email: Sylvester@emergingmed.com
	Miami Beach
	CCOP - Mount Sinai Medical Center
		Michael Schwartz	Ph: 305-674-2625
			Email: info@msccop.com
	Orlando
	Florida Hospital Cancer Institute at Florida Hospital Orlando
		Robert J Sollaccio	Ph: 407-303-5623
	M.D. Anderson Cancer Center at Orlando
		Daniel J Buchholz	Ph: 321-841-7246
Georgia
	Atlanta
	Georgia Cancer Center for Excellence at Grady Memorial Hospital
		Jerome C. Landry	Ph: 404-489-9164
	Gainesville
	Northeast Georgia Medical Center
		Frank G. Lake	Ph: 770-219-8800
			Email: cancerpatient.navigator@nghs.com
	Savannah
	Nancy N. and J. C. Lewis Cancer and Research Pavilion at St. Joseph's/Candler
		John A Pablo	Ph: 912-819-5704
Hawaii
	Honolulu
	Cancer Research Center of Hawaii
		Jeffrey L. Berenberg	Ph: 808-586-2979
	Hawaii Medical Center - East
		Jeffrey L. Berenberg	Ph: 808-586-2979
	Queen's Cancer Institute at Queen's Medical Center
		Jeffrey L. Berenberg	Ph: 808-586-2979
Idaho
	Boise
	Mountain States Tumor Institute at St. Luke's Regional Medical Center
		Stephen C Smith	Ph: 215-574-3173
	Twin Falls
	Mountain States Tumor Institute at St. Luke's
		Stephen C Smith	Ph: 215-574-3173
Illinois
	Arlington Heights
	Northwest Community Hospital
		Stephen S. Nigh	Ph: 847-618-4968
	Chicago
	Creticos Cancer Center at Advocate Illinois Masonic Medical Center
		Deepti A. Singh	Ph: 773-296-5360
	Robert H. Lurie Comprehensive Cancer Center at Northwestern University
		William Small	Ph: 312-695-1301
			Email: cancer@northwestern.edu
	Rush Cancer Institute at Rush University Medical Center
		Ross Allen Abrams	Ph: 312-942-5498
			Email: clinical_trials@rush.edu
	University of Chicago Cancer Research Center
		Stanley L Liauw	Ph: 773-834-7424
	University of Illinois Cancer Center
		Neeta K Venepalli	Ph: 312-355-3046
	Harvey
	Ingalls Cancer Care Center at Ingalls Memorial Hospital
		Sulochana D Yalavarthi	Ph: 708-915-4673
			Email: clinicaltrials@ingalls.org
	Maywood
	Cardinal Bernardin Cancer Center at Loyola University Medical Center
		Bahman Emami	Ph: 708-226-4357
	Naperville
	Edward Hospital Cancer Center
		Alexander Hantel	Ph: 630-646-6075
	Peoria
	OSF Saint Francis Medical Center Radiation Oncology Service at the Central Illinois Comprehensive CC
		Nguyet A Le-Lindqwister	Ph: 800-793-2262
	OSF St. Francis Medical Center
		Nguyet A Le-Lindqwister	Ph: 800-793-2262
	Springfield
	Cancer Institute at St. John's Hospital
		Cathy L. Clausen	Ph: 217-525-5666
			Email: diana.weyhenmeyer@st-johns.org
	Regional Cancer Center at Memorial Medical Center
		James L. Wade	Ph: 217-876-4740
			Email: kcheek@dmhhs.org
	Urbana
	Carle Cancer Center at Carle Foundation Hospital
		Kalika P. Sarma	Ph: 800-446-5532
Indiana
	Elkhart
	Elkhart General Hospital
		Robin Zon	Ph: 574-234-5123
	Goshen
	Center for Cancer Care at Goshen General Hospital
		James A. Wheeler	Ph: 574-535-2858
	South Bend
	CCOP - Northern Indiana CR Consortium
		Robin Zon	Ph: 574-234-5123
	Memorial Hospital of South Bend
		Robin Zon	Ph: 574-234-5123
Iowa
	Ames
	McFarland Clinic, PC
		Joseph James Merchant	Ph: 515-239-2621
	Des Moines
	John Stoddard Cancer Center at Iowa Methodist Medical Center
		Robert J Behrens	Ph: 888-244-6061
			Email: sherrijr@iora.org
	Mercy Cancer Center at Mercy Medical Center - Des Moines
		Robert J Behrens	Ph: 888-244-6061
			Email: sherrijr@iora.org
	Sioux City
	Siouxland Hematology-Oncology Associates, LLP
		Donald Bruce Wender	Ph: 712-252-0088
Kansas
	Topeka
	Cotton-O'Neil Cancer Center
		David E Einspahr	Ph: 785-270-4963
	Wichita
	Via Christi Cancer Center at Via Christi Regional Medical Center
		Shaker R. Dakhil	Ph: 316-262-4467
Kentucky
	Lexington
	Central Baptist Hospital
		Firas B Badin	Ph: 859-260-6425
Louisiana
	New Orleans
	CCOP - Ochsner
		Roland B Hawkins	Ph: 888-562-4763
	Tulane Cancer Center at Tulane University Hospital and Clinic
		Michael J Burdick	Ph: 504-988-6121
Maryland
	Baltimore
	Alvin and Lois Lapidus Cancer Institute at Sinai Hospital
		Mayer Gorbaty	Ph: 800-888-8823
	Greenebaum Cancer Center at University of Maryland Medical Center
		William F. Regine	Ph: 800-888-8823
	St. Agnes Hospital Cancer Center
		Richard S. Hudes	Ph: 410-368-2910
	Salisbury
	Peninsula Regional Medical Center
		Matthew L Snyder	Ph: 866-922-6237
Massachusetts
	Boston
	Boston University Cancer Research Center
		Lisa A. Kachnic	Ph: 617-638-8265
Michigan
	Ann Arbor
	University of Michigan Comprehensive Cancer Center
		Mary U Feng	Ph: 800-865-1125
	Kalamazoo
	West Michigan Cancer Center
		Raymond Sterling Lord	Ph: 269-373-7458
Minnesota
	Fridley
	Mercy and Unity Cancer Center at Unity Hospital
		Paul Sperduto	Ph: 952-993-1517
			Email: MMCCOP@parknicollet.com
	Maplewood
	Minnesota Oncology - Maplewood
		Paul Sperduto	Ph: 952-993-1517
			Email: MMCCOP@parknicollet.com
	Rochester
	Mayo Clinic Cancer Center
		Michael G. Haddock	Ph: 507-538-7623
	Saint Paul
	Regions Hospital Cancer Care Center
		Paul Sperduto	Ph: 952-993-1517
			Email: MMCCOP@parknicollet.com
	United Hospital
		Paul Sperduto	Ph: 952-993-1517
			Email: MMCCOP@parknicollet.com
Mississippi
	Jackson
	University of Mississippi Cancer Clinic
		P. G. Shankar Giri	Ph: 601-815-6700
	Pascagoula
	Regional Cancer Center at Singing River Hospital
		James E. Clarkson	Ph: 228-809-5292
Missouri
	Columbia
	Ellis Fischel Cancer Center at University of Missouri - Columbia
		Carl E. Freter	Ph: 573-882-7440
	Saint Louis
	Missouri Baptist Cancer Center
		Alan Philip Lyss	Ph: 800-392-0936
	Springfield
	Hulston Cancer Center at Cox Medical Center South
		Robert L Carolla	Ph: 417-269-4520
Montana
	Billings
	Billings Clinic Cancer Center - 801 N 29th Street
		Benjamin Thomas Marchello	Ph: 800-648-6274
Nebraska
	Kearney
	Good Samaritan Cancer Center at Good Samaritan Hospital
		Fishel Z Liberman	Ph: 308-865-7963
	Omaha
	Methodist Estabrook Cancer Center
		Tien-Shew W Huang	Ph: 402-354-5144
Nevada
	Las Vegas
	CCOP - Nevada Cancer Research Foundation
		John Allan Ellerton	Ph: 702-731-8274
	Comprehensive Cancer Centers of Nevada - Central Valley
		Raul T Meoz	Ph: 702-731-8274
	Reno
	Renown Institute for Cancer at Renown Regional Medical Center
		Daniel W Weed	Ph: 775-982-4400
New Hampshire
	Manchester
	Elliot Regional Cancer Center at Elliot Hospital
		Brian R Knab	Ph: 603-663-1800
New Jersey
	Basking Ridge
	Memorial Sloan-Kettering Cancer Center - Basking Ridge
		Karyn A Goodman	Ph: 212-639-7202
	Livingston
	St. Barnabas Medical Center Cancer Center
		Delia Radovich	Ph: 973-322-2470
	Mount Holly
	Virtua Fox Chase Health Cancer Program at Virtua Memorial Hospital Burlington County
		Lemuel S. Ariaratnam	Ph: 888-847-8823
	Ridgewood
	Valley Hospital - Ridgewood
		Thomas J. Rakowski	Ph: 201-634-5792
New York
	Albany
	New York Oncology Hematology, PC - Albany
		Vivek S Kavadi	Ph: 281-277-5200
	Canandiaqua
	Sands Cancer Center
		Yuhchyau Chen	Ph: 585-275-5830
	Commack
	Memorial Sloan-Kettering Cancer Center
		Karyn A Goodman	Ph: 212-639-7202
	Glens Falls
	Charles R. Wood Cancer Center at Glens Falls Hospital
		John P Stoutenburg	Ph: 518-926-6700
	Middletown
	Tucker Center for Cancer Care at Orange Regional Medical Center
		Jeffrey M. Stewart	Ph: 845-342-7609
	New York
	Memorial Sloan-Kettering Cancer Center
		Karyn A Goodman	Ph: 212-639-7202
	Rochester
	Daisy Marquis Jones Radiation Oncology Center at Highland Hospital of Rochester
		Yuhchyau Chen	Ph: 585-275-5830
	James P. Wilmot Cancer Center at University of Rochester Medical Center
		Yuhchyau Chen	Ph: 585-275-5830
	Rockville Centre
	Memorial Sloan-Kettering Cancer Center - Rockville Centre
		Karyn A Goodman	Ph: 212-639-7202
	Sleepy Hollow
	Memorial Sloan-Kettering Cancer Center at Phelps Memorial Hospital Center
		Karyn A Goodman	Ph: 212-639-7202
North Carolina
	Charlotte
	Blumenthal Cancer Center at Carolinas Medical Center
		John S Salmon	Ph: 704-355-2884
	Concord
	Batte Cancer Center at Northeast Medical Center
		John S Salmon	Ph: 704-355-2884
	Greenville
	Leo W. Jenkins Cancer Center at ECU Medical School
		Clinton H Leinweber	Ph: 252-744-2391
	Kinston
	Kinston Medical Specialists
		Peter R. Watson	Ph: 252-559-2200
	Raleigh
	Rex Cancer Center at Rex Hospital
		Justin J Wu	Ph: 919-784-7209
Ohio
	Akron
	McDowell Cancer Center at Akron General Medical Center
		Mitchell Lee Fromm	Ph: 330-344-6348
	Summa Center for Cancer Care at Akron City Hospital
		Charles A Kunos	Ph: 800-641-2422
	Barberton
	Barberton Citizens Hospital
		Charles A Kunos	Ph: 800-641-2422
	Cincinnati
	University of Cincinnati
		Kevin P. Redmond	Ph: 513-558-4553
			Email: uchealthnews@uc.edu
	Cleveland
	MetroHealth Cancer Care Center at MetroHealth Medical Center
		Bruce J. Averbook	Ph: 216-778-8526
			Email: kbauchens@metrohealth.org
	Columbus
	Grant Medical Center Cancer Care
		J. Philip Kuebler	Ph: 502-361-8496
	Riverside Methodist Hospital Cancer Care
		J. Philip Kuebler	Ph: 614-566-3275
	Zangmeister Center
		J. Philip Kuebler	Ph: 502-361-8496
	Elyria
	Mercy Cancer Center - Elyria
		Rex B Mowat	Ph: 517-265-0116
	Maumee
	Northwest Ohio Oncology Center
		Rex B Mowat	Ph: 517-265-0116
	Ravenna
	Robinson Radiation Oncology
		Mitchell Lee Fromm	Ph: 330-344-6348
	Salem
	Cancer Care Center, Incorporated
		William F. Demas	Ph: 330-615-4132
	Sylvania
	Flower Hospital Cancer Center
		Rex B Mowat	Ph: 517-265-0116
	West Chester
	University Pointe
		Kevin P. Redmond	Ph: 513-558-4553
			Email: uchealthnews@uc.edu
	Wooster
	Cancer Treatment Center
		William F. Demas	Ph: 330-615-4132
Oklahoma
	Oklahoma City
	Oklahoma University Cancer Institute
		Terence S. Herman	Ph: 405-271-4272
			Email: julie-traylor@ouhsc.edu
Oregon
	Clackamas
	Clackamas Radiation Oncology Center
		Matthew C Solhjem	Ph: 503-215-6412
	Glesham
	Legacy Mount Hood Medical Center
		Andrew Y Kee	Ph: 507-538-7623
	Portland
	CCOP - Columbia River Oncology Program
		Matthew C Solhjem	Ph: 503-215-6412
	Legacy Good Samaritan Hospital & Comprehensive Cancer Center
		Andrew Y Kee	Ph: 507-538-7623
	Providence Cancer Center at Providence Portland Medical Center
		Matthew C Solhjem	Ph: 503-215-6412
	Providence St. Vincent Medical Center
		Matthew C Solhjem	Ph: 503-215-6412
	The Dalles
	Celilo Cancer Center at Mid-Columbia Medical Center
		Keith J. Stelzer	Ph: 541-296-7585
Pennsylvania
	Abington
	Rosenfeld Cancer Center at Abington Memorial Hospital
		Wayne H Pinover	Ph: 215-481-2402
	Bryn Mawr
	Bryn Mawr Hospital
		Paul B. Gilman	Ph: 484-476-2649
			Email: wellenbachj@mlhs.org
	Danville
	Geisinger Cancer Institute at Geisinger Health
		Thomas J Gergel	Ph: 570-271-5251
	Drexel Hill
	Delaware County Regional Cancer Center at Delaware County Memorial Hospital
		Rachelle M. Lanciano	Ph: 610-284-8237
			Email: jolene.garney@crozer.org
	Easton
	Easton Regional Cancer Center at Easton Hospital
		Rajen P Oza	Ph: 610-250-4000
	Gettysburg
	Adams Cancer Center
		Amit B. Shah	Ph: 877-441-7957
	Hanover
	Cherry Tree Cancer Center
		Amit B. Shah	Ph: 877-441-7957
	Media
	Riddle Memorial Hospital Cancer Center
		Adam C Berger	Ph: 215-955-6084
	Paoli
	Cancer Center of Paoli Memorial Hospital
		Paul B. Gilman	Ph: 484-476-2649
			Email: wellenbachj@mlhs.org
	Philadelphia
	Kimmel Cancer Center at Thomas Jefferson University - Philadelphia
		Adam C Berger	Ph: 215-955-6084
	West Reading
	McGlinn Family Regional Cancer Center at Reading Hospital and Medical Center
		Albert Yuen	Ph: 610-988-9323
	Wynnewood
	Lankenau Cancer Center at Lankenau Hospital
		Paul B. Gilman	Ph: 484-476-2649
			Email: wellenbachj@mlhs.org
	York
	WellSpan Health
		Amit B. Shah	Ph: 877-441-7957
Rhode Island
	Providence
	Northmain Radiation Oncology
		Howard Safran	Ph: 401-793-2224
	Rhode Island Hospital Comprehensive Cancer Center
		Howard Safran	Ph: 401-793-2224
South Carolina
	Charleston
	Hollings Cancer Center at Medical University of South Carolina
		David T Marshall	Ph: 843-792-9321
	Greenville
	Cancer Centers of the Carolinas - Faris Road
		David L Grisell	Ph: 864-241-6251
	CCOP - Greenville
		David L Grisell	Ph: 864-241-6251
	Greer
	Cancer Centers of the Carolinas - Greer Radiation Oncology
		David L Grisell	Ph: 864-241-6251
	Seneca
	Cancer Centers of the Carolinas - Seneca
		David L Grisell	Ph: 864-241-6251
	Spartanburg
	Gibbs Regional Cancer Center at Spartanburg Regional Medical Center
		Patricia C Griffin	Ph: 800-486-5941
South Dakota
	Rapid City
	Rapid City Regional Hospital
		Michael J Swartz	Ph: 605-716-3982
			Email: research@rcrh.org
Tennessee
	Nashville
	Vanderbilt-Ingram Cancer Center
		A. Bapsi Chakravarthy	Ph: 800-811-8480
Texas
	Amarillo
	Harrington Cancer Center
		Stewart Allen Sharp	Ph: 806-359-4673
			Email: ryokubaitis@harringtoncc.org
	Arlington
	Texas Oncology, PA at Texas Cancer Center - Arlington South
		Vivek S Kavadi	Ph: 281-277-5200
	Austin
	Texas Oncology - Midtown Austin
		Vivek S Kavadi	Ph: 281-277-5200
	Bedford
	Texas Oncology, PA at Harris Center HEB
		Vivek S Kavadi	Ph: 281-277-5200
	Fort Worth
	Klabzuba Cancer Center at Harris Methodist Fort Worth Hospital
		Vivek S Kavadi	Ph: 281-277-5200
	Galveston
	University of Texas Medical Branch
		Todd A Swanson	Ph: 409-772-1950
			Email: clinical.research@utmb.edu
	Longview
	Longview Cancer Center
		Vivek S Kavadi	Ph: 281-277-5200
	San Antonio
	Cancer Care Centers of South Texas - Northeast
		Vivek S Kavadi	Ph: 281-277-5200
	Sherman
	Texas Oncology, PA at Texas Cancer Center - Sherman
		Vivek S Kavadi	Ph: 281-277-5200
	Sugar Land
	Texas Oncology, PA at Texas Oncology Cancer Center Sugar Land
		Vivek S Kavadi	Ph: 281-277-5200
	Tyler
	Tyler Cancer Center
		Vivek S Kavadi	Ph: 281-277-5200
Utah
	Murray
	Jon and Karen Huntsman Cancer Center at Intermountain Medical Center
		R. Jeffrey Lee	Ph: 801-507-3950
	Ogden
	Val and Ann Browning Cancer Center at McKay-Dee Hospital Center
		R. Jeffrey Lee	Ph: 801-507-3950
	Provo
	Utah Valley Regional Medical Center - Provo
		R. Jeffrey Lee	Ph: 801-507-3950
	Saint George
	Dixie Regional Medical Center - East Campus
		R. Jeffrey Lee	Ph: 801-507-3950
	Salt Lake City
	Huntsman Cancer Institute at University of Utah
		Christopher J Anker	Ph: 801-581-4477
			Email: clinical.trials@hci.utah.edu
	Utah Cancer Specialists at UCS Cancer Center
		R. Jeffrey Lee	Ph: 801-507-3950
Virginia
	Norfolk
	Sentara Cancer Institute at Sentara Norfolk General Hospital
		Scott S Williams	Ph: 757-388-2406
	Virginia Beach
	Coastal Cancer Center at Sentara Virginia Beach General Hospital
		Scott S Williams	Ph: 757-388-2406
Washington
	Spokane
	Cancer Care Northwest - Spokane South
		Christopher M Lee	Ph: 509-228-1083
	Tacoma
	CCOP - Northwest
		Yoshio Inoue	Ph: 253-403-2394
	Vancouver
	Legacy Salmon Creek Medical Center
		Andrew Y Kee	Ph: 507-538-7623
	Northwest Cancer Specialists at Vancouver Cancer Center
		Matthew C Solhjem	Ph: 503-215-6412
	Southwest Washington Medical Center Cancer Center
		Matthew C Solhjem	Ph: 503-215-6412
West Virginia
	Charleston
	West Virginia University Medical School - Charleston
		Steven J. Jubelirer	Ph: 304-388-9944
	Wheeling
	Schiffler Cancer Center at Wheeling Hospital
		Jon David Pollock	Ph: 304-243-6442
Wisconsin
	Antigo
	Langlade Memorial Hospital
		Darryl R. Barton	Ph: 877-405-6866
	Green Bay
	St. Mary's Hospital Medical Center - Green Bay
		Gregory M. Cooley	Ph: 920-433-8889
	St. Vincent Hospital Regional Cancer Center
		Gregory M. Cooley	Ph: 920-433-8889
	La Crosse
	Gundersen Lutheran Center for Cancer and Blood
		Kurt Oettel	Ph: 608-775-2385
			Email: cancerctr@gundluth.org
	Milwaukee
	Froedtert Hospital and Medical College of Wisconsin
		Beth Ann Erickson	Ph: 414-805-4380
	Wausau
	University of Wisconcin Cancer Center at Aspirus Wausau Hospital
		Darryl R. Barton	Ph: 877-405-6866
Canada
Ontario
	Ottawa
	Ottawa Hospital Regional Cancer Centre - Civic Campus
		Jason R Pantarotto	Ph: 613-761-4395
			Email: info@ohri.ca

Link to the current ClinicalTrials.gov record.
NLM Identifer NCT01013649
Information obtained from ClinicalTrials.gov on March 19, 2013